Carregant...
Six‐Month Use of Droxidopa for Neurogenic Orthostatic Hypotension
BACKGROUND: Droxidopa is approved for adult patients with symptomatic neurogenic orthostatic hypotension (nOH); there is limited information regarding effects on symptoms, outcomes, and quality of life (QOL) beyond two weeks of treatment. OBJECTIVE: Examine the real‐world experience of patients taki...
Guardat en:
| Publicat a: | Mov Disord Clin Pract |
|---|---|
| Autors principals: | , , , , , , , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley & Sons, Inc.
2019
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6417751/ https://ncbi.nlm.nih.gov/pubmed/30949555 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/mdc3.12726 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|